Overall Survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jianxiang Wang, Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Menghe Yuan, Taishi Sakatani, Takeshi Kadokura, Masato Takeuchi, Masanori Kosako, Xiao Ma, Larisa Girshova, Jerome Tan, Sergey Bondarenko, Lily Wong Lee Lee, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou
Leukemia 38(11) 2410-2418
The phase 3 COMMODORE trial evaluated gilteritinib versus salvage chemotherapy (SC) in a predominantly Asian relapsed/refractory (R/R) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) patient population. The primary endpoint was overall survival (OS); secondary endpoints included event-free survival (EFS) and complete remission (CR) rate. As of June 30, 2020 (interim analysis: 32.2 months after study initiation), 234 patients were randomized (gilteritinib, n = 116; SC, n = 118). Median OS was significantly longer with gilteritinib versus SC (9.6 vs. 5.0 months; HR 0.566 [95% CI: 0.392, 0.818]; p = 0.00211) with a median follow-up of 10.3 months. Median EFS was also significantly longer with gilteritinib (2.8 vs. 0.6 months; HR 0.551 [95% CI: 0.395, 0.769]; p = 0.00004). CR rates with gilteritinib and SC were 16.4% and 10.2%, respectively; composite CR rates were 50.0% and 20.3%, respectively. Exposure-adjusted grade ≥3 adverse event (AE) rates were lower with gilteritinib (58.38 events/patient-year [E/PY]) versus SC (168.30 E/PY). Common AEs with gilteritinib were anemia (77.9%) and thrombocytopenia (45.1%). Gilteritinib plasma concentration peaked ~4 h postdose; ~3-fold accumulation occurred with multiple dosing. The COMMODORE trial demonstrated that gilteritinib significantly improved OS and EFS in predominantly Asian patients, validating the outcomes of gilteritinib from the ADMIRAL trial in R/R FLT3mut+ AML.
2 个 Figure · 3 个 KM 面板
Fig. 2. Overall survival by treatment group (intention-to-treat population) and subgroup analysis of overall survival. A Kaplan–Meier curve of overall survival (primary endpoint). The intention-to-treat population includes all randomized patients. The predetermined two-sided significance level was 0.00454 based on the number of observed overall survival events. B Subgroup analyses of overall survival. Preselected high-intensity therapy included FLAG or MEC; preselected low-intensity chemotherapy consisted of LoDAC. CI confidence interval, CRc composite complete remission, ECOG Eastern Cooperative Oncology Group, FLAG fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor, FLT3 FMS-like tyrosine kinase 3, HR hazard ratio, HSCT hematopoietic stem cell transplantation, IRT interactive response technology, ITD internal tandem duplication, LoDAC low-dose cytarabine, MEC mitoxantrone, etoposide, and intermediate-dose cytarabine, NE not estimable, SC salvage chemotherapy, TKD tyrosine kinase domain.
Fig. 3. Event-free survival by treatment group (intention-to-treat population). Kaplan–Meier curve of event-free survival (a key secondary endpoint). The predetermined two-sided significance level was 0.04011. CI confidence interval, HR hazard ratio.
Fig. 3 · Panel Event-Free_Survival
Panel Event-Free_Survival 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。